| scholarly article | Q13442814 |
| P50 | author | Luca Antonio Aldrighetti | Q88601450 |
| P2093 | author name string | Michele Reni | |
| Stefano Cereda | |||
| Eugenio Villa | |||
| Paolo Passoni | |||
| Roberto Nicoletti | |||
| Maria G Viganò | |||
| P2860 | cites work | Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer | Q33214444 |
| Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma | Q33337313 | ||
| Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma | Q33343774 | ||
| Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma | Q33359823 | ||
| Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial | Q33359839 | ||
| Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma | Q33361810 | ||
| Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study | Q33362191 | ||
| Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial | Q33363800 | ||
| Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial | Q33365628 | ||
| Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial | Q33366562 | ||
| Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma | Q33371777 | ||
| Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study | Q33493886 | ||
| Biliary tract cancers. | Q33760399 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer | Q34063503 | ||
| A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. | Q34554801 | ||
| Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials | Q34576456 | ||
| Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience | Q35757432 | ||
| Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. | Q36615965 | ||
| Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial | Q36624106 | ||
| Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma | Q42451927 | ||
| Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer | Q44448996 | ||
| CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study | Q44470251 | ||
| Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer | Q44508387 | ||
| Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas | Q44896529 | ||
| Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma | Q45236677 | ||
| A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. | Q46630423 | ||
| S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study | Q46795508 | ||
| Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma | Q46846035 | ||
| Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. | Q52935096 | ||
| Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy. | Q54502319 | ||
| Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours | Q61868335 | ||
| Comprehensive criteria for assessing therapy-induced toxicity | Q68920718 | ||
| 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract | Q72398245 | ||
| Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study | Q72447982 | ||
| Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer | Q72821837 | ||
| A phase II study of cisplatin in patients with biliary tract carcinoma | Q72830952 | ||
| Interaction between gemcitabine and mitomycin-C in vitro | Q73384931 | ||
| A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma | Q74681551 | ||
| Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study | Q79261123 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorouracil | Q238512 |
| adenocarcinoma | Q356033 | ||
| cisplatin | Q412415 | ||
| P304 | page(s) | 2208-2214 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma | |
| P478 | volume | 116 |
| Q50176693 | A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer. |
| Q27023881 | Ampullary cancer: an overview |
| Q36094595 | Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells |
| Q35222202 | Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress |
| Q45363859 | Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer. |
| Q49588315 | Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma |
| Q36822722 | Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells |
| Q43846460 | Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma. |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q90355694 | Therapeutic options for ampullary carcinomas. A review |
| Q35854505 | Tumors of ampulla of Vater: A case series and review of chemotherapy options |
Search more.